UBS AM
MRSN

UBS AM’s Mersana Therapeutics MRSN Stock Holding History

UBS AM’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,103
Closed -$130K – 2581
2023
Q3 		$130K Hold
4,103
– – ﹤0.01% 2549
2023
Q2 		$422K Hold
4,103
– – ﹤0.01% 2376
2023
Q1 		$422K Hold
4,103
– – ﹤0.01% 2376
2022
Q4 		$601K Buy
4,103
+568
+16% +$96K ﹤0.01% 2101
2022
Q3 		$597K Hold
3,535
– – ﹤0.01% 2263
2022
Q2 		$408K Hold
3,535
– – ﹤0.01% 2374
2022
Q1 		$353K Buy
3,535
+1,798
+104% +$210K ﹤0.01% 2553
2021
Q4 		$270K Hold
1,737
– – ﹤0.01% 2702
2021
Q3 		$409K Hold
1,737
– – ﹤0.01% 2557
2021
Q2 		$590K Buy
1,737
+154
+10% +$58.3K ﹤0.01% 2470
2021
Q1 		$640K Sell
1,583
-1,144
-42% -$555K ﹤0.01% 2298
2020
Q4 		$1.81M Buy
2,727
+209
+8% +$116K ﹤0.01% 1723
2020
Q3 		$1.17M Buy
2,518
+433
+21% +$219K ﹤0.01% 1776
2020
Q2 		$1.22M Buy
+2,085
New +$712K ﹤0.01% 1718

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UBS AM's MRSN Position: Q4 2023 in Review

UBS AM sold out of Mersana Therapeutics (MRSN) in Q4 2023, closing a stake of 4,103 shares — an estimated $130K sold.

UBS AM first reported a position in MRSN in Q2 2020 and held it in 14 quarters. The position peaked at $1.81M in Q4 2020. 105 funds tracked by Wall St. Rank hold MRSN as of Q4 2023.

  • UBS AM reported no remaining Mersana Therapeutics position as of Q4 2023 after selling out during the quarter.
  • UBS AM sold 4,103 Mersana Therapeutics shares in Q4 2023, an estimated $130K.
  • UBS AM first reported a position in Mersana Therapeutics in Q2 2020 and held it in 14 quarters.
  • UBS AM's Mersana Therapeutics position peaked at $1.81M in Q4 2020.
  • 105 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2023.

Based on UBS AM's 13F filing for Q4 2023, filed 14 Feb 2024.